Avac Event

Are We PrEPared this Time? Ensuring a Swift Translation of Research into Community Impact

First approved in 2012, roll out of oral PrEP has been slow, uneven, and marked by troubling and unacceptable uptake disparities across race/ethnicity, gender and geography. In 2019, less than 25 percent of people eligible for PrEP in the US received a prescription. Late last year, the US FDA approved a new PrEP agent called Apretude, an injectable, longer-acting PrEP option. While hopes are high for this intervention, it is replete with challenges from both the user as well as the delivery sides of the equation.

The AIDS Foundation Chicago, AVAC and an array of speakers spoke on what must happen to ensure swift translation of positive research results into community impact. What follows are a set of resources from the webinar.


Recording / Slides

Sign On Letter
Requesting that the Biden administration include in his upcoming budget request $400 million to create a National PrEP Grant Program. Organizations can sign here.

Resources Shared